Bookmark and Share
naloxonazine (CID 9576413) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(5)
 
 
Inactive(4)
 
 
Unspecified(130)
 
 
Top Targets:
7TM GPCR Srx(16)
 
 
 
7TM GPCR Srsx(15)
 
 
p450(8)
 
 
NR LBD ER(2)
 
 
7tm 2(2)
 
 
BioAssay Types:
Confirmatory(116)
 
 
 
Literature(3)
 
 
 
BioActivity Types:
IC50(116)
 
 
 
EC50(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 139    Data Row: 139   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID124960987]
IC50 0.0072DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625163, Type: confirmatory]Mu-type opioid receptor [gi:2851402]
View
2
[SID124960987]
IC50 0.085DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625162, Type: confirmatory]Kappa-type opioid receptor [gi:116242691]
View
3
[SID124960987]
IC50 0.136DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) [AID625161, Type: confirmatory]Delta-type opioid receptor [gi:311033488]
View
4
[SID124960987]
EC50 16Cytotoxicity against BESM cells after 88 hrs by HTS assay [AID547621, Type: Literature]
View
5
[SID124960987]
EC50 17Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay [AID547622, Type: Literature]
View
6
[SID124960987]
Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells [AID547804, Type: Literature]
View
7
[SID124960987]
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
8
[SID124960987]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: confirmatory]
View
9
[SID124960987]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: confirmatory]
View
10
[SID124960987]
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
11
[SID124960987]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: confirmatory]
View
12
[SID124960987]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: confirmatory]
View
13
[SID124960987]
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
14
[SID124960987]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: confirmatory]
View
15
[SID124960987]
IC50 DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) [AID625197, Type: confirmatory]
View
16
[SID124960987]
IC50 DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) [AID625210, Type: confirmatory]
View
17
[SID124960987]
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
18
[SID124960987]
IC50 DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) [AID625212, Type: confirmatory]
View
19
[SID124960987]
IC50 DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: confirmatory]
View
20
[SID124960987]
IC50 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: confirmatory]
View